Can testosterone replacement therapy (TRT) in males cause weight gain?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 12, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Testosterone Replacement Therapy and Weight Changes in Males

Testosterone replacement therapy (TRT) in males typically leads to weight loss rather than weight gain, particularly in obese men with testosterone deficiency. 1

Effects of Testosterone on Body Composition

Testosterone has significant effects on body composition through several mechanisms:

  • Fat Mass: TRT reduces overall fat mass, particularly visceral and truncal adiposity 1, 2
  • Lean Body Mass: TRT increases lean muscle mass 1
  • Metabolic Effects: Testosterone improves insulin sensitivity and glucose metabolism 3

Evidence from Clinical Studies

Multiple studies have demonstrated favorable body composition changes with TRT:

  • A study of middle-aged obese men showed decreased visceral fat mass without changes in body mass or subcutaneous fat after 8 months of testosterone treatment 2
  • Long-term testosterone therapy in men with testosterone deficiency produces significant and sustained weight loss, marked reduction in waist circumference and BMI 1
  • TRT improves components of metabolic syndrome, including insulin resistance and lipid profiles 3

Mechanisms Behind Weight Changes

Testosterone affects weight and body composition through several pathways:

  • Improved mitochondrial function and increased energy utilization 1
  • Enhanced protein anabolism and decreased protein catabolism 4, 5
  • Increased red blood cell production through stimulation of erythropoietic factors 4, 5
  • Regulation of important proteins involved in glycolysis, glycogen synthesis, and lipid metabolism 3

Clinical Considerations for TRT

When considering TRT for patients with hypogonadism:

Patient Selection

  • Morning free testosterone by equilibrium dialysis should be frankly low on at least 2 separate assessments 6
  • Complete hypogonadism workup to rule out etiologies unrelated to obesity 6

Monitoring Parameters

  • Target Total Testosterone: 450-600 ng/dL 7
  • Hematocrit: Monitor at baseline, 3-6 months, then annually; discontinue if exceeds 54% 7
  • Body Composition: Track weight, BMI, and waist circumference 6

Common Pitfalls and Precautions

  • Erythrocytosis/Polycythemia: Most common side effect, occurring in 2.8-43.8% of patients depending on formulation 7
  • Formulation Differences: Injectable testosterone has the highest risk of polycythemia (43.8%), followed by gel preparations (11.3-17.9%), and transdermal patches (2.8-5.5%) 7
  • Contraindications: Active prostate or breast cancer, hematocrit >50%, severe untreated sleep apnea, severe lower urinary tract symptoms, uncontrolled heart failure 7

Clinical Bottom Line

TRT in hypogonadal men typically leads to beneficial body composition changes including decreased fat mass and increased lean mass. The evidence strongly suggests that properly administered TRT in appropriate candidates results in weight loss rather than weight gain, particularly in obese men with testosterone deficiency. Careful monitoring for potential side effects, especially polycythemia, is essential during treatment.

References

Research

Testosterone and weight loss: the evidence.

Current opinion in endocrinology, diabetes, and obesity, 2014

Research

The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.

International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992

Research

Testosterone: a metabolic hormone in health and disease.

The Journal of endocrinology, 2013

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Evaluation and Management of Low Libido in Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.